Cover Image
市場調查報告書

肺癌治療藥的全球市場:2016∼2020年

Global Lung Cancer Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 261559
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
肺癌治療藥的全球市場:2016∼2020年 Global Lung Cancer Therapeutics Market 2016-2020
出版日期: 2016年11月18日 內容資訊: 英文 101 Pages
簡介

肺癌成為已開發國家,發展中國家中死亡的主要原因,抽煙有很大影響。全球肺癌治療藥市場,預計2016∼2020年達約111億9,000萬美元規模。

本報告提供全球肺癌治療藥市場相關調查,市場趨勢與課題,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • 經濟負擔
  • 肺癌的種類
  • 診斷
  • SCLC的分期
  • NSCLC的分期
  • 主要的購買標準

第6章 開發平台分析

第7章 市場情況

  • 全球肺癌治療藥市場
  • 波特的五力分析

第8章 各疾病市場區隔

  • NSCLC
  • SCLC

第9章 各分子市場區隔

  • 小分子
  • 生技藥品

第10章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場的要素

  • 標靶治療的需求擴大
  • 長期的專利獨佔伴隨的暢銷藥物的存在
  • 分子生物標記的鑑定的進步擴大患者群
  • 對查核點抑制劑引進的模式轉移

第12章 促進要素的影響

第13章 市場課題

  • 替代療法越來越受歡迎
  • 高成本導致低的引進率
  • 藥物的副作用

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式

第17章 主要供應商分析

  • F. Hoffmann-La Roche
  • Eli Lilly
  • AstraZeneca
  • Pfizer
  • Celgene
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR10849

About Lung Cancer Therapeutics

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavio's analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hofmann-La Roche
  • Eli Lilly
  • AstraZeneca
  • Pfizer
  • Celgene

Other Prominent Vendors

  • Abbvie
  • Aetna
  • Agennix
  • Allergan
  • Amgen
  • ARIAD Pharmaceuticals
  • Astellas Pharma
  • Betta Pharmaceuticals
  • BeyondSpring Pharmaceuticals
  • BioNumerik Pharmaceuticals
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb
  • Celldex
  • CTI BioPharma
  • Eisai
  • GlaxoSmithKline
  • GTx
  • Helsinn
  • Hutchison Medipharma
  • Ionis Pharmaceuticals
  • Kadmon Corporation
  • MabVax
  • Merck
  • Novartis
  • NovaRx Corporation
  • OncoGeneX
  • Ono Pharmaceutical
  • OSE Immunotherapeutics
  • OSI Pharmaceuticals
  • Peregrine
  • PharmaMar
  • Pierre Fabre
  • Qiagen
  • Recombio
  • Samsung Bioepis
  • Sanofi
  • SFJ Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Sumitomo Dainippon Pharma
  • Synta
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Xcovery

Market driver

  • Growing demand for targeted therapies
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of alternative therapeutics
  • For a full, detailed list, view our report

Market trend

  • Emergence of nanomedicine platform for the treatment of lung cancer
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Economic burden
  • Types of lung cancer
  • Diagnosis
  • Staging of SCLC
  • Staging of NSCLC
  • Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global lung cancer therapeutics market
  • Five forces analysis

PART 08: Market segmentation by disease type

  • NSCLC
  • Global NSCLC market overview
  • SCLC
  • Global SCLC market overview

PART 09: Market segmentation by type of molecule

  • Small molecules
  • Biologics

PART 10: Geographical segmentation

  • Lung cancer therapeutics market in Americas
  • Lung cancer therapeutics market in EMEA
  • Lung cancer therapeutics market in APAC

PART 11: Market drivers

  • Growing demand for targeted therapies
  • Presence of blockbuster drugs coupled with longer patent exclusivities
  • Advancements in identification of molecular biomarkers increasing patient pool
  • Paradigm shifts toward the adoption of checkpoint inhibitors

PART 12: Impact of drivers

PART 13: Market challenges

  • Growing popularity of alternative therapeutics
  • High costs leading to low adoption rate
  • Adverse effects of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of nanomedicine platform for the treatment of lung cancer
  • Advent of miRNA therapeutics in the treatment of lung cancer
  • Growing strategic alliances for late-stage pipeline
  • Growing approvals in lung cancer therapeutics market

PART 16: Vendor landscape

  • Competitive scenario

PART 17: Key vendor analysis

  • F. Hoffmann-La Roche
  • Eli Lilly
  • AstraZeneca
  • Pfizer
  • Celgene
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of global lung cancer therapeutics market
  • Exhibit 03: Snapshot of lung cancer
  • Exhibit 04: Types of lung cancer
  • Exhibit 05: Main diagnostic procedures to determine presence of lung cancer
  • Exhibit 06: Staging of SCLC
  • Exhibit 07: Illustration of stages of NSCLC disease
  • Exhibit 08: Key buying criteria for lung cancer therapeutics
  • Exhibit 09: Factors affecting adoption rates of lung cancer therapeutics
  • Exhibit 10: Pipeline analysis of key vendors in global lung cancer therapeutics market
  • Exhibit 11: Percentage share of drug candidates by stage of development
  • Exhibit 12: Phase III pipeline portfolio: Global lung cancer therapeutics market
  • Exhibit 13: Phase II pipeline portfolio: Global lung cancer therapeutics market
  • Exhibit 14: Phase I pipeline portfolio: Global lung cancer therapeutics market
  • Exhibit 15: Global lung cancer therapeutics market snapshot
  • Exhibit 16: Analysis of global lung cancer therapeutics market
  • Exhibit 17: Global lung cancer therapeutics market size and forecast 2015-2020 ($ billions)
  • Exhibit 18: Opportunity analysis of global lung cancer therapeutics market
  • Exhibit 19: Opportunity analysis in developed and emerging markets
  • Exhibit 20: Five forces analysis
  • Exhibit 21: Segmentation of global lung cancer therapeutics market by disease type 2015 and 2020
  • Exhibit 22: Life cycle analysis of key segments in global lung cancer therapeutics market 2015
  • Exhibit 23: Types of NSCLC
  • Exhibit 24: Potential drugs/drug candidates in global NSCLC therapeutics market
  • Exhibit 25: Key drivers impacting market growth in NSCLC
  • Exhibit 26: Global NSCLC therapeutics market size and forecast 2015-2020 ($ billions)
  • Exhibit 27: Opportunity analysis in global NSCLC market
  • Exhibit 28: Key points in SCLC
  • Exhibit 29: Key drivers impacting market growth in SCLC
  • Exhibit 30: Global SCLC therapeutics market size and forecast 2015-2020 ($ billions)
  • Exhibit 31: Opportunity analysis in global SCLC therapeutics market
  • Exhibit 32: Segmentation of global lung cancer therapeutics market by type of molecule 2015
  • Exhibit 33: Global lung cancer therapeutics market by geographical segmentation 2015-2020
  • Exhibit 34: Segmentation of global lung therapeutics market based on geography 2015 and 2020
  • Exhibit 35: Lung cancer therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 36: Lung cancer therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Key trends across various countries in Americas
  • Exhibit 38: Lung cancer therapeutics market size and forecast in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Drivers in lung cancer therapeutics market in EMEA
  • Exhibit 40: Key strategic initiatives in various countries in EMEA
  • Exhibit 41: Lung cancer therapeutics market size and forecast in APAC 2015-2020 ($ billions)
  • Exhibit 42: Key drivers and challenges in APAC
  • Exhibit 43: YoY growth rate of Avastin 2015
  • Exhibit 44: Performance of blockbuster drugs in 2015
  • Exhibit 45: Patent exclusivities of few blockbuster drugs
  • Exhibit 46: Recent launches of checkpoint inhibitors
  • Exhibit 47: Impact of drivers
  • Exhibit 48: Alternative therapies for lung cancer therapeutics
  • Exhibit 49: Costs of few lung cancer drugs ($)
  • Exhibit 50: Force field analysis of drivers and challenges in global lung cancer therapeutics market
  • Exhibit 51: Impact of drivers and challenges
  • Exhibit 52: Trend analysis in global lung cancer therapeutics market
  • Exhibit 53: Key factors driving adoption of nanomedicine
  • Exhibit 54: Factors driving adoption of miRNA therapeutics
  • Exhibit 55: Key deals in global lung cancer therapeutics market
  • Exhibit 56: Recent approvals of lung cancer therapeutics
  • Exhibit 57: Competitive analysis in global lung cancer therapeutics market
  • Exhibit 58: Market penetration of various lung cancer therapeutics manufacturers in global (2015)
  • Exhibit 59: Regional analysis of vendors in global lung cancer therapeutics market
  • Exhibit 60: Vendors ranking in global lung cancer therapeutics market
  • Exhibit 61: F. Hoffmann-La Roche: Key highlights
  • Exhibit 62: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 63: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
  • Exhibit 66: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
  • Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Tarceva 2013-2015 ($ billions)
  • Exhibit 68: F. Hoffmann-La Roche: Geographic segmentation of Tarceva by revenue 2015
  • Exhibit 69: Eli Lilly: Key highlights
  • Exhibit 70: Eli Lilly: Strength assessment
  • Exhibit 71: Eli Lilly: Strategy assessment
  • Exhibit 72: Eli Lilly: Opportunity assessment
  • Exhibit 73: Eli Lilly: YoY revenue and growth rate of Alimta 2013-2015 ($ billions)
  • Exhibit 74: Eli Lilly: Geographic segmentation by revenue of Alimta 2015
  • Exhibit 75: Eli Lilly: YoY and growth rate of Cyramza 2014-2015 ($ millions)
  • Exhibit 76: Eli Lilly: Geographic segmentation by revenue of Cyramza 2015
  • Exhibit 77: AstraZeneca: Key highlights
  • Exhibit 78: AstraZeneca: Strength assessment
  • Exhibit 79: AstraZeneca: Strategy assessment
  • Exhibit 80: AstraZeneca: Opportunity assessment
  • Exhibit 81: AstraZeneca: YoY revenue and growth rate of Iressa 2013-2015 ($ billions)
  • Exhibit 82: AstraZeneca: Geographic segmentation of Iressa 2013-2015 (% share)
  • Exhibit 83: Pfizer: Key highlights
  • Exhibit 84: Pfizer: Strength assessment
  • Exhibit 85: Pfizer: Strategy assessment
  • Exhibit 86: Pfizer: Opportunity assessment
  • Exhibit 87: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions)
  • Exhibit 88: Celgene: Key highlights
  • Exhibit 89: Celgene: Strength assessment
  • Exhibit 90: Celgene: Strategy assessment
  • Exhibit 91: Celgene: Opportunity assessment
  • Exhibit 92: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)
Back to Top